NRNP 6665 Final Exam Test Questions | Questions with 100%
Verified Answers | Latest Update 2026/2027
Question: Question 18:
Christine is a 9-year-old female who presents for care after
having been placed in the local foster care system. She has
been in and out of foster care for the last 4 years after her
parents were killed in an automobile accident. Christine has
been placed in a variety of homes and residential care
facilities. The PMHNP recognizes that Christine is at high risk
for:
Answer:
Question: Question 7:
Caylee is a 5-year-old girl who is referred for evaluation by
child protective services. She was recently removed from her
biological family and placed in foster care, as her home
environment was reportedly unsafe due to conditions of
extreme neglect. Her foster mother reports that Caylee is very
quiet and withdrawn and always appears sad and
disinterested in her surroundings; however, she becomes very
irritable when anything unexpected or unplanned occurs. The
foster mother became very concerned when it appeared that
Caylee was hallucinating. The PMHNP considers that:
Answer:
,Question: Question 2:
Debi is a 15-year-old girl who is currently being treated for
depression. Her parents have been very proactive and
involved in her care, and Debi has achieved remission 2
months after beginning treatment with a combination of
pharmacotherapy and cognitive behavioral therapy. While
counseling Debi's parents about important issues in
management, the PMHNP advises that:
Answer:
Question: Agomelatine
Answer:
Brand: Valdoxan
-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase to 50 mg/day at bedtime
Question: Amitriptyline (Elavil)
Answer:
Tricyclic antidepressant.
Question: Aripiprazole (Abilify)
Answer:
Treatment for depression. Atypical antipsychotic. "Dopamine stabilizer". Dopamine
receptor antagonist in high concentration and also stimulates increase of dopamine in
low concentrations. Side effects: insomnia, akathisia.
Question: Brexpiprazole (Rexulti)
Answer:
Treatment for depression. Atypical antipsychotic
,Question: Bupropion (Wellbutrin)
Answer:
Antidepressant and smoking cessation aid, It can treat depression and help people quit
smoking. It can also prevent depression caused by seasonal affective disorder (SAD).
Question: Citalopram (Celexa)
Answer:
Antidepressant, SSRI: 20-40 mg qd.
Question: Clomipramine (Anafranil)
Answer:
-Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)
-Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradrenaline reuptake inhibitor
-Increases serotonergic neurotransmission by blocking the serotonin reuptake pump
(transporter), -Desensitization of serotonin receptors, especially serotonin 1A receptors
-Increases noradrenergic neurotransmission by blocking the norepinephrine reuptake
pump (transporter), -Desensitization of beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in the frontal cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of the brain
**FDA Approved for Pediatrics in tx Obsessive-compulsive disorder (OCD) (ages 10 and
older)
*Off-Label for Pediatric Use: Depression, Severe and treatment-resistant, depression,
Cataplexy syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day
, Question: Cyamemazine (Tercian)
Answer:
Treatment for depression.
-Known as cyamepromazine
-Typical antipsychotic drug of the phenothiazine class.
-Treatment for schizophrenia
and psychosis-associated
anxiety
-Behaves like an atypical
antipsychotic, due to its
potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
-Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist,
serotonin dopamine antagonist)
-Commonly Prescribed for (not FDA approved):
-Schizophrenia
-Anxiety associated with psychosis (short-term)
-Anxiety associated with nonpsychotic disorders, including mood disorders and
personality disorders (short-term)
-Severe depression
-Bipolar disorder
-Other psychotic disorders
-Acute agitation/aggression (injection)
-Benzodiazepine withdrawal
Question: Desiprimine (Norpramine)
Answer:
Treats depression
Brand: Norpramin
-TCA
-Norepinephrine noradrenaline reuptake inhibitor.
-FDA approved for treating depression.
-Off-label: Anxiety, Insomnia,
Neuropathic pain/chronic pain, Treatment-resistant depression.
-More potent inhibitor of norepinephrine reuptake pump than serotonin reuptake pump
(serotonin transporter).
-May have immediate effects in treating insomnia or anxiety.
-If it is not working within 6-8 weeks for depression, it may require a dosage increase or it
may not work at all
-100-200 mg/day (for depression)
50-150 mg/day (for chronic pain).
Verified Answers | Latest Update 2026/2027
Question: Question 18:
Christine is a 9-year-old female who presents for care after
having been placed in the local foster care system. She has
been in and out of foster care for the last 4 years after her
parents were killed in an automobile accident. Christine has
been placed in a variety of homes and residential care
facilities. The PMHNP recognizes that Christine is at high risk
for:
Answer:
Question: Question 7:
Caylee is a 5-year-old girl who is referred for evaluation by
child protective services. She was recently removed from her
biological family and placed in foster care, as her home
environment was reportedly unsafe due to conditions of
extreme neglect. Her foster mother reports that Caylee is very
quiet and withdrawn and always appears sad and
disinterested in her surroundings; however, she becomes very
irritable when anything unexpected or unplanned occurs. The
foster mother became very concerned when it appeared that
Caylee was hallucinating. The PMHNP considers that:
Answer:
,Question: Question 2:
Debi is a 15-year-old girl who is currently being treated for
depression. Her parents have been very proactive and
involved in her care, and Debi has achieved remission 2
months after beginning treatment with a combination of
pharmacotherapy and cognitive behavioral therapy. While
counseling Debi's parents about important issues in
management, the PMHNP advises that:
Answer:
Question: Agomelatine
Answer:
Brand: Valdoxan
-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase to 50 mg/day at bedtime
Question: Amitriptyline (Elavil)
Answer:
Tricyclic antidepressant.
Question: Aripiprazole (Abilify)
Answer:
Treatment for depression. Atypical antipsychotic. "Dopamine stabilizer". Dopamine
receptor antagonist in high concentration and also stimulates increase of dopamine in
low concentrations. Side effects: insomnia, akathisia.
Question: Brexpiprazole (Rexulti)
Answer:
Treatment for depression. Atypical antipsychotic
,Question: Bupropion (Wellbutrin)
Answer:
Antidepressant and smoking cessation aid, It can treat depression and help people quit
smoking. It can also prevent depression caused by seasonal affective disorder (SAD).
Question: Citalopram (Celexa)
Answer:
Antidepressant, SSRI: 20-40 mg qd.
Question: Clomipramine (Anafranil)
Answer:
-Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)
-Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradrenaline reuptake inhibitor
-Increases serotonergic neurotransmission by blocking the serotonin reuptake pump
(transporter), -Desensitization of serotonin receptors, especially serotonin 1A receptors
-Increases noradrenergic neurotransmission by blocking the norepinephrine reuptake
pump (transporter), -Desensitization of beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in the frontal cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of the brain
**FDA Approved for Pediatrics in tx Obsessive-compulsive disorder (OCD) (ages 10 and
older)
*Off-Label for Pediatric Use: Depression, Severe and treatment-resistant, depression,
Cataplexy syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day
, Question: Cyamemazine (Tercian)
Answer:
Treatment for depression.
-Known as cyamepromazine
-Typical antipsychotic drug of the phenothiazine class.
-Treatment for schizophrenia
and psychosis-associated
anxiety
-Behaves like an atypical
antipsychotic, due to its
potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
-Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist,
serotonin dopamine antagonist)
-Commonly Prescribed for (not FDA approved):
-Schizophrenia
-Anxiety associated with psychosis (short-term)
-Anxiety associated with nonpsychotic disorders, including mood disorders and
personality disorders (short-term)
-Severe depression
-Bipolar disorder
-Other psychotic disorders
-Acute agitation/aggression (injection)
-Benzodiazepine withdrawal
Question: Desiprimine (Norpramine)
Answer:
Treats depression
Brand: Norpramin
-TCA
-Norepinephrine noradrenaline reuptake inhibitor.
-FDA approved for treating depression.
-Off-label: Anxiety, Insomnia,
Neuropathic pain/chronic pain, Treatment-resistant depression.
-More potent inhibitor of norepinephrine reuptake pump than serotonin reuptake pump
(serotonin transporter).
-May have immediate effects in treating insomnia or anxiety.
-If it is not working within 6-8 weeks for depression, it may require a dosage increase or it
may not work at all
-100-200 mg/day (for depression)
50-150 mg/day (for chronic pain).
